Haloperidol and Dexamethasone Towards Postoperative Nausea and Pain in Adult After Laparoscopy

Haloperidol Compared to Dexamethasone in Lowering Postoperative Nausea and Vomiting and Pain in Adult After Laparoscopy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05246631

Enrollment

Registered

2022-02-18

Start date

2020-01-01

Completion date

2020-07-30

Last updated

2022-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopy, Postoperative Nausea and Vomiting

Keywords

dexamethasone, haloperidol, nausea, pain, vomiting

Brief summary

This study aim to find out the effectiveness of 1 mg intravenous haloperidol compared to 5 mg intravenous dexamethasone to prevent the occurrence of nausea and vomiting also as pain control in adult patients after laparoscopic surgery.

Detailed description

Eighty subjects (n=40 for each group) scheduled for laparoscopic-assisted surgery were enrolled in a randomized double-blind clinical trial. One milligram intravenous haloperidol was given one hour before the end of surgery, while 5 mg intravenous dexamethasone was given right after induction. The occurrence of Postoperative Nausea and Vomiting (PONV) and visual analog scale (VAS) pain score were recorded.

Interventions

DRUGDexamethasone injection

Group A consisted of patients given 5 mg intravenous dexamethasone after induction.

DRUGHaloperidol Injection

Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* underwent laparoscopic surgery (gynecology, digestive, or urology surgery) * American Society of Anesthesiologist (ASA) physical status 1-3

Exclusion criteria

* psychological or neurological disorders (routine haloperidol consumption) * history of allergic reaction to dexamethasone or haloperidol * diabetes mellitus * did not give the consent

Design outcomes

Primary

Measure	Time frame	Description
Nausea and Vomiting	Within 24 hours postoperative	Number of patients experiencing nausea and vomiting postoperative

Secondary

Measure	Time frame	Description
Pain and VAS	0-2 hours, 2-6 hours, 6-12 hours, and 12-24 hours postoperative	Visual Analog Scale (VAS) score, the minimum score is 0 and the maximum score is 10. The higher scores mean a worse outcome

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026